| 摘要: |
| 目的 观察雷西莫特对特应性皮炎小鼠的治疗效果，并探究其作用机制。方法 30只BALB/c小鼠随机分为空白组、模型组、治疗组，每组10只。模型组及治疗组小鼠耳部予卡泊三醇搽剂（连续14 d，每天2 nmol）诱导特应性皮炎模型，同时模型组予200 μL PBS每天腹腔注射、治疗组予50 nmol雷西莫特（溶于200 μL PBS）每天腹腔注射；空白组小鼠不给予任何处理。实验第15天观察各组小鼠耳部皮损红斑、肿胀及鳞屑情况；采用H-E染色及甲苯胺蓝染色观察皮损组织炎症细胞浸润情况；采用ELISA检测血清IgE、IL-4、IL-13水平；采用qPCR检测皮损组织中胸腺基质淋巴细胞生成素（TSLP）、γ干扰素mRNA的表达。结果 与空白组相比，模型组小鼠耳部皮肤出现明显肿胀发红、鳞屑，血清中IgE、IL-4、IL-13水平均升高（P均＜0.01），说明小鼠特应性皮炎模型构建成功。与模型组小鼠相比，治疗组小鼠耳部皮肤红肿、鳞屑及炎症细胞浸润情况均好转，血清IgE、IL-4、IL-13水平均降低（P均＜0.05），皮损组织中γ干扰素mRNA表达量升高（P＜0.05）。皮损组织中TSLP mRNA表达量在模型组和治疗组间差异无统计学意义（P＞0.05）。结论 雷西莫特可改善特应性皮炎小鼠的皮损症状，其机制可能与调节辅助性T细胞（Th）1/Th2免疫反应、影响相关细胞因子的表达有关。 |
| 关键词: 雷西莫特 特应性皮炎 Toll样受体 Th1细胞 Th2细胞 |
| DOI：10.16781/j.CN31-2187/R.20220037 |
| 投稿时间：2022-01-10修订日期：2022-04-29 |
| 基金项目:促进市级医院临床技能与临床创新能力三年行动计划(SHDC2020CR1014B),海军军医大学(第二军医大学)第一附属医院"234学科攀峰计划"(2019YXK028) |
|
| Effect of resiquimod on atopic dermatitis model mice |
| SUN Gang,ZHU Xiao-chen,HE Xu,BI Xin-ling* |
(Department of Dermatology, The First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200433, China
*Corresponding author) |
| Abstract: |
| ObjectiveTo observe the therapeutic effect of resiquimod on atopic dermatitis model mice and explore its mechanisms.MethodsThirty BALB/c mice were randomly divided into blank group, model group, and treatment group, with 10 mice in each group. The atopic dermatitis model was induced by calcipotriol liniment (2 nmol daily for 14 d) on the ear in the model group and treatment group. At the same time, the model group was intraperitoneally injected with 200 μL phosphate-buffered saline (PBS) every day, and the treatment group was intraperitoneally injected with 50 nmol resiquimod (dissolved in 200 μL PBS) every day. The mice in the blank group was not given any treatment. On the 15th day, the erythema, swelling and scale of the ear lesions of mice in each group were observed. The infiltration of inflammatory cells in skin lesions was observed by hematoxylin-eosin staining and toluidine blue staining. The levels of serum immunoglobulin E (IgE), interleukin (IL)-4 and IL-13 were detected by enzyme-linked immunosorbent assay. The expression of thymic stromal lymphopoietin (TSLP) and interferon γ mRNA in the skin lesions was detected by quantitative polymerase chain reaction.ResultsCompared with the blank group, erythema, swelling and scale appeared on the ear skin of mice in the model group, and the levels of serum IgE, IL-4 and IL-13 were significantly increased (all P < 0.01), indicating that the atopic dermatitis model was successfully constructed. Compared with the model group, the erythema, swelling, scale and infiltration of inflammatory cells of the ear lesions in the treatment group were improved, the levels of serum IgE, IL-4 and IL-13 were significantly decreased (all P < 0.05), and the mRNA expression of interferon γ was significantly increased (P < 0.05). The mRNA expression of TSLP in skin lesions was not significantly different between the model group and treatment group (P > 0.05).ConclusionResiquimod can improve the symptoms of atopic dermatitis mice, and its mechanism may be related to regulating helper T cell (Th)1/Th2 immune response and affecting the expression of related cytokines. |
| Key words: resiquimod atopic dermatitis Toll-like receptor Th1 cells Th2 cells |
